Business description: Avacta Group Plc

Avacta Group plc is a United Kingdom-based life sciences company focused on improving healthcare outcomes through targeted cancer treatments and diagnostics. The Company has two segments: Therapeutics and Diagnostics. The Therapeutics segment is a clinical stage oncology biotech division harnessing therapeutic platforms to develop novel, highly targeted cancer drugs. The Diagnostics segment is focused on supporting healthcare professionals and broadening access to diagnostics. It has two platforms: preICISION and Affimer. The Company's preICISION platform is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumors compared with healthy tissues. The preICISION platform harnesses this tumor specific protease to activate preICISION peptide drug conjugates and preICISION antibody/Affimer drug conjugates in the tumor microenvironment. Its lead preICISION program AVA6000, a peptide drug conjugate form of doxorubicin, is in Phase 1 studies.

Number of employees: 151

Sales by Activity: Avacta Group Plc

Fiscal Period: December 2020 (GBP) 2021 (GBP) 2022 (GBP) 2023 (GBP) 2024 (GBP)

Therapeutics

1.62M 2.16M 5.48M 2.06M 113K

Diagnostics

519K 779K 4.17M 21.19M -

Animal Health

1.49M - - - -

Geographical breakdown of sales: Avacta Group Plc

Fiscal Period: December 2020 (GBP) 2021 (GBP) 2022 (GBP) 2023 (GBP) 2024 (GBP)

South Korea

- 1.4M 5.48M 2.06M 113K

Rest of World

- - - 613K -

France

- - 1.3M 4.12M -

Rest of Asia

- 74K 7K - -

Rest of Europe

685K 111K 158K 3.69M -

North America

402K 815K 179K 21K -

Asia

1.47M - - - -

United Kingdom

1.08M 540K 2.53M 12.75M -

Executive Committee: Avacta Group Plc

Manager TitleAgeSince
Chief Executive Officer 56 2024-03-31
Director of Finance/CFO 51 2025-01-21
Chief Tech/Sci/R&D Officer - 2026-02-08
Chief Tech/Sci/R&D Officer - 2025-06-30

Composition of the Board of Directors: Avacta Group Plc

Director TitleAgeSince
Director/Board Member 60 2020-02-02
Director/Board Member 71 2021-08-16
Director/Board Member 56 2022-03-17
Chairman 59 2024-06-23
Director/Board Member 59 2025-05-27
Director/Board Member 58 2025-05-27

Shareholders: Avacta Group Plc

NameEquities%Valuation
Hargreaves Lansdown Fund Managers Ltd.
8.027 %
35,351,000 8.027 % 30 M p
Lombard Odier Asset Management (Europe) Ltd.
2.648 %
11,662,726 2.648 % 10 M p
Conifer Management LLC
2.648 %
11,662,726 2.648 % 10 M p
IG Markets Ltd.
2.588 %
11,398,000 2.588 % 10 M p
HSBC Global Asset Management (UK) Ltd.
1.607 %
7,079,000 1.607 % 6 M p

Company details: Avacta Group Plc

Avacta Group Plc

Scale Space

W12 7RZ, London

+44 203 9110353

http://www.avacta.com
address Avacta Group Plc(AVCT)

Bio Therapeutic Drugs

Change 5d. change 1-year change 3-years change Capi.($)
+2.78%+11.78%+80.49%-46.76% 443M
+0.71%+9.47%+34.62%+104.43% 51.73B
+0.26%+5.46%+101.15%+24.51% 47.14B
-4.34%-9.99%+106.59%+776.06% 33.11B
+1.08%+10.99%-2.80%-23.28% 24.89B
-0.59%+5.77%+74.53%-32.48% 19.66B
-0.22%+5.00%+44.35%-34.72% 17.86B
+6.89%+4.91%+69.52%+212.29% 16.22B
+1.29%+9.89%-19.17%+1,245.22% 16.17B
+6.97%+3.08%+61.68% - 14.44B
Average +1.48%+5.46%+55.10%+247.25% 24.17B
Weighted average by Cap. +0.63%+4.45%+58.02%+237.52%
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
0.7200GBP
Average target price
0.7925GBP
Spread / Average Target
+10.07%

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. AVCT Stock
  4. Company Avacta Group Plc